It has been reported that the third-generation EGFR inhibitor osimertinib, but not the first- or second-generation EGFR inhibitors gefitinib, erlotinib, or afatinib, is active against exon 19 and 21 mutations as well as the T790M mutation-positive disease21–25 and that the efficacy of EGFR inhibitors in EGFR-mutation NSCLC is limited by other salvage signals, including STAT3 and Src-YES-associated protein 1 (YAP1) signaling26. Here, STAT3 is linked to non-small cell lung carcinoma.